RAD51 and lung cancer: To confirm this conjecture, we designed wild-type and mutant luciferase reporter plasmids based on the binding site of FOXM1 to the Rad51 promoter and detected the luciferase activity after co-transfecting them with siRNA targeting FOXM1 in lung cancer cells.